AIMS: The aim of this study was to evaluate the feasibility of liver transplantation (OLT) in human immunodeficiency virus (HIV), hepatitis C virus (HCV) coinfected patients in Italy. METHODS: Between September 2002 and April 2006, 12 HIV(+) coinfected patients (11 men, mean age 42 years) underwent OLT at our Institute. Eleven (91%) patients were HCV-positive and one was hepatitis B virus-positive. Pre-OLT plasma HIV 1-RNA level was undetectable and CD4(+) T-cell count >200 cells/microL for 3 months in all patients. Six patients had to stop highly active antiretroviral therapy (HAART) before OLT because of liver disease severity (n = 2) and for hepato cellular carcinoma (n = 4). RESULTS: The actuarial 1-, 2-, and 3-year survival rates were 83.3%, 58.3%, and 58.3%, respectively, which were significantly lower than those observed among HIV-negative patients transplanted in our center. Six patients are alive with a mean follow-up of 26 months (range: 5 to 46 months). We recorded a low rate of opportunistic infections and rejection. All alive patients have low levels of HIV RNA, and the CD4(+) T-cell counts increased after OLT. Nine patients developed early recurrence of hepatitis C requiring combination therapy with peg-interferon plus ribavirin. Significant improvement in the quality of life was observed in 7/11 patients. CONCLUSIONS: OLT in HIV-positive patients was feasible with good results in the short and medium term. Early severe HCV recurrence may be observed. Key challenges for the management of HIV(+) patients after transplantation included treatment of severe HCV recurrence and attention to the pharmacological interactions of HAART with immunosuppressive drugs.
AIMS: The aim of this study was to evaluate the feasibility of liver transplantation (OLT) in human immunodeficiency virus (HIV), hepatitis C virus (HCV) coinfectedpatients in Italy. METHODS: Between September 2002 and April 2006, 12 HIV(+) coinfected patients (11 men, mean age 42 years) underwent OLT at our Institute. Eleven (91%) patients were HCV-positive and one was hepatitis B virus-positive. Pre-OLT plasma HIV 1-RNA level was undetectable and CD4(+) T-cell count >200 cells/microL for 3 months in all patients. Six patients had to stop highly active antiretroviral therapy (HAART) before OLT because of liver disease severity (n = 2) and for hepato cellular carcinoma (n = 4). RESULTS: The actuarial 1-, 2-, and 3-year survival rates were 83.3%, 58.3%, and 58.3%, respectively, which were significantly lower than those observed among HIV-negative patients transplanted in our center. Six patients are alive with a mean follow-up of 26 months (range: 5 to 46 months). We recorded a low rate of opportunistic infections and rejection. All alive patients have low levels of HIV RNA, and the CD4(+) T-cell counts increased after OLT. Nine patients developed early recurrence of hepatitis C requiring combination therapy with peg-interferon plus ribavirin. Significant improvement in the quality of life was observed in 7/11 patients. CONCLUSIONS: OLT in HIV-positivepatients was feasible with good results in the short and medium term. Early severe HCV recurrence may be observed. Key challenges for the management of HIV(+) patients after transplantation included treatment of severe HCV recurrence and attention to the pharmacological interactions of HAART with immunosuppressive drugs.
Authors: C S Coffin; P G Stock; L M Dove; C L Berg; N N Nissen; M P Curry; M Ragni; F G Regenstein; K E Sherman; M E Roland; N A Terrault Journal: Am J Transplant Date: 2010-03-19 Impact factor: 8.086
Authors: C M J Drapeau; A Pan; C Bellacosa; G Cassola; M P Crisalli; M De Gennaro; S Di Cesare; F Dodi; G Gattuso; L Irato; P Maggi; M Pantaleoni; P Piselli; L Soavi; E Rastrelli; E Tacconelli; N Petrosillo Journal: Infection Date: 2009-10 Impact factor: 3.553
Authors: Giuseppe Maria Ettorre; Roberto Santoro; Giovanni Vennarecci; Pasquale Lepiane; Mario Antonini; Eugenio Santoro Journal: Updates Surg Date: 2011-07-19
Authors: Joseph T King; Melissa F Perkal; Ronnie A Rosenthal; Adam J Gordon; Stephen Crystal; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; David Rimland; Michael S Simberkoff; Amy C Justice Journal: JAMA Surg Date: 2015-04 Impact factor: 14.766
Authors: Norah A Terrault; Michelle E Roland; Thomas Schiano; Lorna Dove; Michael T Wong; Fred Poordad; Margaret V Ragni; Burc Barin; David Simon; Kim M Olthoff; Lynt Johnson; Valentina Stosor; Dushyantha Jayaweera; John Fung; Kenneth E Sherman; Aruna Subramanian; J Michael Millis; Douglas Slakey; Carl L Berg; Laurie Carlson; Linda Ferrell; Donald M Stablein; Jonah Odim; Lawrence Fox; Peter G Stock Journal: Liver Transpl Date: 2012-06 Impact factor: 5.799
Authors: Michelle E Roland; Burc Barin; Shirish Huprikar; Barbara Murphy; Douglas W Hanto; Emily Blumberg; Kim Olthoff; David Simon; William D Hardy; George Beatty; Peter G Stock Journal: AIDS Date: 2016-01-28 Impact factor: 4.177